Dudediligence.

Replimune Group, Inc

REPLNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$53.1MSep ’24−$66.3MDec ’24−$74.1MMar ’25−$86.7MJun ’25−$83.1MSep ’25−$70.9MDec ’25−$73.2MMar ’26−$69.8MJun ’26
Fiscal years, by the month each ended
LineMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating income−$118.3M−$177.1M−$234.8M−$261.6M−$319.9M
Net income−$118.0M−$174.3M−$215.8M−$247.3M−$313.9M
Operating cash flow−$82.2M−$128.1M−$185.5M−$192.3M−$280.3M
Free cash flow−$84.5M−$130.3M−$191.1M−$198.9M−$284.6M
Cash$105.9M$146.6M$74.5M$111.1M$209.0M
Debt$0.00$28.6M$44.8M$46.4M$83.3M
Shares outstanding47.3M56.7M61.4M77.1M82.7M